Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560120	EYEPOINT PHARMS	Vehicles for delivery of biologically active substances	Sep, 2022 (1 year, 25 days ago)
US6960346	EYEPOINT PHARMS	Vehicles for delivery of biologically active substances	Jul, 2023 (2 months ago)
US10799642	EYEPOINT PHARMS	Dose guides for injection syringe	May, 2032 (8 years from now)
US10028965	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (10 years from now)
US10159683	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (10 years from now)
US10022502	EYEPOINT PHARMS	Dose guides for injection syringe	Jun, 2034 (10 years from now)
US11097061	EYEPOINT PHARMS	Systems, kits and methods for loading and delivering a small volume dose from a syringe	Jun, 2039 (15 years from now)

Dexycu Kit is owned by Eyepoint Pharms.

Dexycu Kit contains Dexamethasone.

Dexycu Kit has a total of 7 drug patents out of which 2 drug patents have expired.

Expired drug patents of Dexycu Kit are:

US7560120
US6960346

Dexycu Kit was authorised for market use on 09 February, 2018.

Dexycu Kit is available in suspension;intraocular dosage forms.

Dexycu Kit can be used as treatment of postoperative inflammation, a method of loading medication into a syringe and delivering the medication to a treatment site.

The generics of Dexycu Kit are possible to be released after 23 June, 2039.

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR